Also trades as: 0K16.L (LSE) · $vol 0M
EOLS NASDAQ
Evolus, Inc.
1W: -2.0%
1M: +24.3%
3M: +47.6%
YTD: -4.0%
1Y: -35.2%
3Y: -33.6%
5Y: -28.8%
$6.09
-0.36 (-5.58%)
Weekly Expected Move ±9.3%
$5
$6
$6
$7
$8
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$401.1M
52W Range3.86-10.62
Volume611,119
Avg Volume1,128,755
Beta1.29
Dividend—
Analyst Ratings
Company Info
CEODavid Moatazedi
Employees372
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2018-02-08
Websiteevolus.com
520 Newport Center Drive
Newport Beach, CA 92660
US
Newport Beach, CA 92660
US
949 284 4555
About Evolus, Inc.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Latest News
Evolus reiterates 2026 net revenue of $327M-$337M while targeting a low to mid-single-digit adjusted EBITDA margin
Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
Evolus (EOLS) Q1 2026 Earnings Transcript
Evolus (EOLS) Q2 2025 Earnings Call Transcript
Here are the major earnings after the close Monday
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Avelar Rui | S-Sale | 3,119 | $4.75 | 2026-03-20 |
| MOATAZEDI DAVID | S-Sale | 13,669 | $4.75 | 2026-03-20 |
| MOATAZEDI DAVID | S-Sale | 116,720 | $4.89 | 2026-03-17 |
| Avelar Rui | S-Sale | 29,996 | $4.89 | 2026-03-17 |
| MOATAZEDI DAVID | M-Exempt | 67,489 | — | 2026-03-16 |